title: Cancer- and chemotherapy-induced anemia.
abstract: Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer- and Chemotherapy-Induced Anemia underwent substantial revisions this year. The purpose of these NCCN Guidelines is twofold: 1) to operationalize the evaluation and treatment of anemia in adult cancer patients, with an emphasis on those who are receiving concomitant chemotherapy, and 2) to enable patients and clinicians to individualize anemia treatment options based on patient condition.
authors.forename: George M
authors.initials: GM
authors.lastname: Rodgers
authors.forename: Pamela Sue
authors.initials: PS
authors.lastname: Becker
authors.forename: Morey
authors.initials: M
authors.lastname: Blinder
authors.forename: David
authors.initials: D
authors.lastname: Cella
authors.forename: Asher
authors.initials: A
authors.lastname: Chanan-Khan
authors.forename: Charles
authors.initials: C
authors.lastname: Cleeland
authors.forename: Peter F
authors.initials: PF
authors.lastname: Coccia
authors.forename: Benjamin
authors.initials: B
authors.lastname: Djulbegovic
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Gilreath
authors.forename: Eric H
authors.initials: EH
authors.lastname: Kraut
authors.forename: Ursula A
authors.initials: UA
authors.lastname: Matulonis
authors.forename: Michael M
authors.initials: MM
authors.lastname: Millenson
authors.forename: Denise
authors.initials: D
authors.lastname: Reinke
authors.forename: Joseph
authors.initials: J
authors.lastname: Rosenthal
authors.forename: Rowena N
authors.initials: RN
authors.lastname: Schwartz
authors.forename: Gerald
authors.initials: G
authors.lastname: Soff
authors.forename: Richard S
authors.initials: RS
authors.lastname: Stein
authors.forename: Gordana
authors.initials: G
authors.lastname: Vlahovic
authors.forename: Alva B
authors.initials: AB
authors.lastname: Weir
mesh_terms: D000740:Anemia / Q000139:chemically induced / Q000209:etiology* / Q000628:therapy; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001803:Blood Transfusion / Q000379:methods; D006397:Hematinics / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008495:Medical Oncology / Q000379:methods* / Q000592:standards*; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy*; D012307:Risk Factors; D065227:Transfusion Reaction
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics